The underlying mechanisms of how TGFβ-activated EMT supports chemoresistance in cancer cells has not been clearly elucidated, but are likely due to increased expression of efflux pumps, DNA repair genes, and effects on major signaling pathways including AKT and TP53 [93, 95]. Here, AKT1 is linked to cancer.